Meiji Yasuda Asset Management Co Ltd. Has $2.48 Million Holdings in Boston Scientific Co. (NYSE:BSX)

Meiji Yasuda Asset Management Co Ltd. grew its holdings in Boston Scientific Co. (NYSE:BSX) by 23.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 32,146 shares of the medical equipment provider’s stock after buying an additional 6,120 shares during the period. Meiji Yasuda Asset Management Co Ltd.’s holdings in Boston Scientific were worth $2,476,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Putnam Investments LLC lifted its holdings in Boston Scientific by 110.5% during the 4th quarter. Putnam Investments LLC now owns 13,067,570 shares of the medical equipment provider’s stock valued at $755,436,000 after purchasing an additional 6,859,280 shares during the last quarter. Capital World Investors raised its position in shares of Boston Scientific by 236.1% in the fourth quarter. Capital World Investors now owns 9,419,829 shares of the medical equipment provider’s stock valued at $544,560,000 after purchasing an additional 6,617,360 shares during the period. Capital Research Global Investors acquired a new stake in shares of Boston Scientific during the 1st quarter worth about $182,897,000. Vanguard Group Inc. boosted its holdings in shares of Boston Scientific by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 127,437,884 shares of the medical equipment provider’s stock worth $8,728,221,000 after buying an additional 1,988,082 shares during the period. Finally, Public Employees Retirement Association of Colorado grew its stake in Boston Scientific by 11,484.5% in the 4th quarter. Public Employees Retirement Association of Colorado now owns 1,705,468 shares of the medical equipment provider’s stock valued at $98,593,000 after buying an additional 1,690,746 shares during the last quarter. 89.07% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have issued reports on BSX shares. Truist Financial raised their price objective on shares of Boston Scientific from $86.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, July 16th. Argus boosted their price target on Boston Scientific from $80.00 to $95.00 and gave the company a “buy” rating in a research note on Tuesday, May 28th. BTIG Research increased their price objective on Boston Scientific from $80.00 to $84.00 and gave the stock a “buy” rating in a research report on Monday, July 15th. Citigroup boosted their target price on shares of Boston Scientific from $90.00 to $92.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Finally, Canaccord Genuity Group raised their price target on shares of Boston Scientific from $83.00 to $88.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Three investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $85.38.

Boston Scientific Stock Up 0.1 %

Shares of BSX opened at $82.57 on Thursday. The firm has a 50 day simple moving average of $78.46 and a two-hundred day simple moving average of $74.45. The company has a market cap of $121.14 billion, a P/E ratio of 69.39, a P/E/G ratio of 2.75 and a beta of 0.79. Boston Scientific Co. has a one year low of $48.35 and a one year high of $84.11. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.61 and a quick ratio of 1.14.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.04. The business had revenue of $4.12 billion during the quarter, compared to the consensus estimate of $4.02 billion. Boston Scientific had a return on equity of 16.59% and a net margin of 12.00%. Boston Scientific’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same period in the prior year, the company earned $0.53 EPS. Research analysts forecast that Boston Scientific Co. will post 2.4 EPS for the current fiscal year.

Insider Transactions at Boston Scientific

In related news, EVP Wendy Carruthers sold 6,983 shares of Boston Scientific stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $81.70, for a total transaction of $570,511.10. Following the sale, the executive vice president now directly owns 37,468 shares of the company’s stock, valued at approximately $3,061,135.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last 90 days, insiders sold 20,949 shares of company stock valued at $1,627,877. 0.50% of the stock is currently owned by insiders.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.